New York State Common Retirement Fund Buys New Position in Inhibrx, Inc. (NASDAQ:INBX)

New York State Common Retirement Fund acquired a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 3,472 shares of the company’s stock, valued at approximately $53,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in Inhibrx during the 4th quarter worth approximately $348,000. Rhumbline Advisers acquired a new stake in Inhibrx during the 4th quarter worth approximately $228,000. Exchange Traded Concepts LLC acquired a new stake in Inhibrx during the 4th quarter worth approximately $148,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Inhibrx during the 4th quarter worth approximately $47,000. 82.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

Inhibrx Price Performance

Shares of INBX stock opened at $13.32 on Friday. The stock has a 50 day simple moving average of $13.57 and a 200-day simple moving average of $14.63. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $35.90.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.